Fig. 2From: Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case–control studySecond PCR results after treatment; Group 1: Early treatment with FPV and HQ, Group 2: Late treatment with FPV and HQ, Group 3: Treatment with only HQBack to article page